Forecasting the long‐term impact of COVID ‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach
Liver International · 2023
DOI: 10.1111/liv.15712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Loreta A Kondili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health, Istituto Superiore di Sanità, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, COVID-19, Hepatitis C. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval….
Abstract (Originalsprache)
Background
Italy has a high HCV prevalence, and despite the approval of a dedicated fund for ‘Experimental screening’ for 2 years, screening has not been fully implemented. We aimed to evaluate the long‐term impact of the persisting delay in HCV elimination after the Coronavirus disease 2019 (COVID‐19) pandemic in Italy.
Methods
We used a mathematical, probabilistic modelling approach evaluating three hypothetical ‘Inefficient’, ‘Efficient experimental’ and ‘WHO Target’ screening scenarios differing by treatment rates over time. A Markov chain for liver disease progression evaluated the number of active infections, decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and HCV liver‐related deaths up to the years 2030 and 2050.
Results
The ‘WHO Target’ scenario estimated 3900 patients with DC and 600 with HCC versus 4400 and 600 cases, respectively, similar for both ‘Inefficient’ and ‘Efficient experimental’ screening up to 2030. A sharp (10‐fold) decrease in DC and HCC was estimated by the ‘WHO Target’ scenario compared with the other two scenarios in 2050; the forecasted number of DC was 420 cases versus 4200 and 3800 and of HCC
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
- Dentistry and Dental Prosthetics, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
- Infectious Diseases Unit, University of Tor Vergata, Rome, Italy.
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
ORCID-Profile: Alessio Aghemo
Förderung
- The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval…
Zitieren
APA
Kondili, L. A., Andreoni, M., Aghemo, A., Mastroianni, C. M., Merolla, R., Gallinaro, V., D'Offizi, G., & Craxì, A. (2023). Forecasting the long‐term impact of COVID ‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach. Liver International. https://doi.org/10.1111/liv.15712
Vancouver
Kondili LA, Andreoni M, Aghemo A, Mastroianni CM, Merolla R, Gallinaro V, et al. Forecasting the long‐term impact of COVID ‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach. Liver International. 2023. doi:10.1111/liv.15712
BibTeX
@article{Kondili2023,
author = {Kondili, Loreta A and Andreoni, Massimo and Aghemo, Alessio and Mastroianni, Claudio Maria and Merolla, Rocco and Gallinaro, Valentina and D'Offizi, Gianpiero and Craxì, Antonio},
title = {Forecasting the long‐term impact of COVID ‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15712}
}
EUVIMED